Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

The FDA has blocked J&J's (JNJ) application to widen the use of its Xarelto blood thinner to...

  • Friday, June 22, 2012, 5:00 AM ET
    The FDA has blocked J&J's (JNJ) application to widen the use of its Xarelto blood thinner to prevent heart attacks and strokes in people with acute coronary syndrome, a market estimated at $1B. J&J said it will work with the FDA to address their questions, indicating it hasn't given up hope of eventually getting the authorization.
Track new comments on this story

This news story has 3 comments:

  •  
    JNJ will work with the FDA.. Wow, what a novel idea. Normally they ignore the FDA and sell the products for years until the law suits are filed. Like the vaginal mess units. Took them years to get caught.

    I know there are fans of this company,but, if you want growth and dividends an have no conscience then buy PM or another known killer !
    22 Jun 2012, 05:21 AM Reply Like
  •  
    Did you forget to take your Risperdal pill this morning?
    22 Jun 2012, 07:55 AM Reply Like
  •  
    Unfortunately, many Pharma companies put profit ahead of patient safety
    22 Jun 2012, 10:24 AM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »